利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.056 秒)

    6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
    12.
    发明授权
    6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors 失效
    6,6-双环取代杂双环蛋白激酶抑制剂

    公开(公告)号：US08367826B2

    公开(公告)日：2013-02-05

    申请号：US13308694

    申请日：2011-12-01

    申请人： Radoslaw Laufer ,  An-Hu Li ,  Mark J. Mulvihill ,  Arno G. Steinig

    发明人： Radoslaw Laufer ,  An-Hu Li ,  Mark J. Mulvihill ,  Arno G. Steinig

    IPC分类号： C07D471/00

    CPC分类号： C07F5/025 ,  C07D471/04 ,  C07D487/04

    摘要： Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.

    摘要翻译： 其中X 1，X 2，X 3，X 4，X 5，X 6，X 7，R 1和Q 1在本文中定义的式及其药学上可接受的盐的化合物抑制IGF-1R酶，并且可用于治疗和/或预防 过度增生性疾病如癌症，炎症，牛皮癣，过敏/哮喘，免疫系统的疾病和状况，中枢神经系统的疾病和状况。

    FUSED BICYCLIC KINASE INHIBITORS
    13.
    发明申请
    FUSED BICYCLIC KINASE INHIBITORS 审中-公开
    熔融双相激酶抑制剂

    公开(公告)号：US20140088114A1

    公开(公告)日：2014-03-27

    申请号：US14117741

    申请日：2012-05-15

    申请人： Meizhong Jin ,  Mark J. Mulvihill ,  Arno G. Steinig ,  Jing WANG

    发明人： Meizhong Jin ,  Mark J. Mulvihill ,  Arno G. Steinig ,  Jing WANG

    IPC分类号： C07D471/04

    CPC分类号： C07D471/04 ,  C07D487/04

    摘要： Compounds of Formula (I), pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by at least one of MET, RON, ALK, IR, or IGF-1R. This Abstract is not limiting of the invention.

    摘要翻译： 式（I）的化合物，其药学上可接受的盐，合成，中间体，制剂及其治疗方法，包括治疗癌症，例如至少部分地由至少一种MET，RON，ALK，IR ，或IGF-1R。 本发明并不限于本发明。

    2-AMINOPYRIDINE KINASE INHIBITORS
    14.
    发明申请
    2-AMINOPYRIDINE KINASE INHIBITORS 失效
    2-氨基吡啶激酶抑制剂

    公开(公告)号：US20090197862A1

    公开(公告)日：2009-08-06

    申请号：US12365325

    申请日：2009-02-04

    申请人： Arno G. Steinig ,  Mark J. Mulvihill ,  Jing Wang ,  Douglas S. Werner ,  Qinghua Weng ,  Julie Kan ,  Heather Coate ,  Xin Chen

    发明人： Arno G. Steinig ,  Mark J. Mulvihill ,  Jing Wang ,  Douglas S. Werner ,  Qinghua Weng ,  Julie Kan ,  Heather Coate ,  Xin Chen

    IPC分类号： A61K31/4439 ,  C07D401/14 ,  C07D417/14 ,  C07D451/02 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04 ,  A61K31/4725 ,  A61K31/5377 ,  A61K31/4545

    CPC分类号： C07D417/14 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/04 ,  C07D451/04

    摘要： 2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.

    摘要翻译： 具有式I结构的2-氨基吡啶化合物和这些化合物的药学上可接受的盐。 式I的化合物抑制动物（包括人）中酪氨酸激酶的活性，并且可用于治疗和/或预防各种疾病和病症。 特别地，本文公开的化合物是激酶抑制剂，特别是但不限于KDR，Tie-2，Flt3，FGFR3，Ab1，Aurora A，c-Src，IGF-1R，ALK，c-MET，RON， PAK1，PAK2和TAK1，并且可用于治疗增殖性疾病，例如但不限于癌症。 本发明还涉及包含治疗有效量的式I化合物或其药学上可接受的盐和药学上可接受的载体的药物组合物。 本发明还涉及通过向患者施用治疗有效量的上述药物组合物来治疗具有由蛋白激酶活性介导的病症的患者的方法。

    2-aminopyridine kinase inhibitors
    16.
    发明授权
    2-aminopyridine kinase inhibitors 失效
    2-氨基吡啶激酶抑制剂

    公开(公告)号：US08178668B2

    公开(公告)日：2012-05-15

    申请号：US12365325

    申请日：2009-02-04

    申请人： Arno G. Steinig ,  Mark J. Mulvihill ,  Jing Wang ,  Douglas S. Werner ,  Qinghua Weng ,  Heather Coate ,  Xin Chen

    发明人： Arno G. Steinig ,  Mark J. Mulvihill ,  Jing Wang ,  Douglas S. Werner ,  Qinghua Weng ,  Heather Coate ,  Xin Chen

    IPC分类号： C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D451/02 ,  C07D471/04 ,  C07D487/04

    CPC分类号： C07D417/14 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/04 ,  C07D451/04

    摘要： 2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors of kinases, in particular, but not limited to, KDR, Tie-2, Flt3, FGFR3, Ab1, Aurora A, c-Src, IGF-1R, ALK, c-MET, RON, PAK1, PAK2, and TAK1, and can be used in the treatment of proliferative diseases, such as, but not limited to, cancer. The present invention is also directed to a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention is further directed to a method of treating a patient having a condition which is mediated by protein kinase activity by administering to the patient a therapeutically effective amount of the above-mentioned pharmaceutical composition.

    摘要翻译： 具有式I结构的2-氨基吡啶化合物和这些化合物的药学上可接受的盐。 式I的化合物抑制动物（包括人）中酪氨酸激酶的活性，并且可用于治疗和/或预防各种疾病和病症。 特别地，本文公开的化合物是激酶抑制剂，特别是但不限于KDR，Tie-2，Flt3，FGFR3，Ab1，Aurora A，c-Src，IGF-1R，ALK，c-MET，RON， PAK1，PAK2和TAK1，并且可用于治疗增殖性疾病，例如但不限于癌症。 本发明还涉及包含治疗有效量的式I化合物或其药学上可接受的盐和药学上可接受的载体的药物组合物。 本发明还涉及通过向患者施用治疗有效量的上述药物组合物来治疗具有由蛋白激酶活性介导的病症的患者的方法。